Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Citrus shows promise for certain childhood cancer

01.12.2004


Orange juice and cancer don’t mix. In fact, the popular citrus drink could become a cocktail to prevent or stop the deadly disease in humans.



Research by Texas Agriculture Experiment Station scientists has shown that citrus compounds called limonoids targeted and stopped neuroblastoma cells in the lab. They now hope to learn the reasons for the stop-action behavior and eventually try the citrus concoction in humans.

Neuroblastomas account for about 10 percent of all cancer in children, Harris said, and is usually a solid tumor in the neck, chest, spinal cord or adrenal gland. The finding in citrus is promising not only for its potential to arrest cancer, but because limonoids induce no side affects, according to Dr. Ed Harris, Experiment Station biochemist who collaborated on the study with Dr. Bhimu Patil, a plant physiologist at the Texas A&M University-Kingsville Citrus Center in Weslaco. "Limonoids are naturally occurring compounds," Harris said. "Unlike other anti-cancer drugs that are toxic, limonoids apparently do not hurt a person. That’s the beautiful potential."


Patil calls citrus fruit "a vast reservoir of anti-carcinogens." As a plant physiologist, he has succeeded in isolating and purifying a number of limonoids from citrus so that the biochemists could evaluate and compare their anti-cancer abilities at the molecular level. "Limonoids are unique to citrus," Patil said. "They are not present in any other fruits or vegetables. My goal is to find the direct benefits of citrus on human health. "

He said a challenging task is to isolate the limonoid compounds, "because some are present in very small concentrations."

In fact, citrus breeders seeking to improve the fruit’s tastiness for consumers and yield for producers led researchers to discover limonoids – eight of which have been characterized from extractions at the Weslaco facility, according to the researchers. "If I ask why one should drink orange juice every day," Harris noted, "almost everyone would say for vitamin C. That’s true, but we also need to learn two new words – flavonoids and limonoids."

Harris explained that flavonoids and limonoids – nutrient-packed pigments that give color and taste to fruit – may work against cancer in any of three ways: prevent it from forming, slow the growth of existing cancer, or kill cancer cells.

"The limonoids, which differ structurally from flavonoids, seem to do all three," he said of tests in his lab by one of Patil’s graduate students, Shibu Poulose, who also worked in Harris’ College Station lab. Their work emphasized the compounds’ ability to kill existing the neuroblastoma cells with the rationale that if the method and time limonoids take to obliterate the cancer could be found, perhaps scientists could exploit it to help cure the disease.

What Poulose found with the extracted limonoid was that the neuroblastoma cells died with relatively small amounts of concentrated limonoids and all in 48 hours or less.

They tested this in several ways. First, the limonoids were put through a test to see whether they would quench the oxygen radicals – cancer-causing substances that are destructive to normal cells. The limonoids appeared to be as effective as vitamin C in some of the tests.

Test of cell viability were more impressive, however. The neuroblastoma cells were all dead within two days with just 5, 10 and 50 micromoles of limonoids. A micromole is about the equivalent of a tiny skin flake. Some limonoids were more effective than others, but all had killing potential. These amounts of limonoids could easily be obtained from a glass of orange or grapefruit juice.

Next, cell viability tests aimed at whether the cell death was caused by apoptosis -- a programmed cell death that spirals in an unstoppable fashion unstoppably once the vulnerable spot on the cell is hit. "Suppose we have cancer and the cancer cell mutates repeatedly until it takes over our organs," he said. "So, a compound comes in and spots those cells with the unusual metabolism and kills them by degrading the cells’ protein and fragmenting their DNA until the cells succumb.

"Apoptosis is beneficial. It’s the immunity system in the body that causes the white cells to recognize things that are not supposed to be there and attack them," Harris explained. Apoptosis early in life removes those white cells that would attack the body’s own protein, for example.

To test this, the researchers applied 1, 5, 10 and 50 micromolar amounts of limonoids to neuroblastoma cells, then put an apoptosis-blocking chemical on an identical comparison set. Neuroblastoma cells with the blocker did not die, indicating that the limonoids trigger apoptosis which in turn results in the cell death. In their tests, the cancer cells treated with limonoids – but not the apoptosis blocker – all died within 36 hours.

The researchers also looked at caspases, destructive enzymes that are activated to cause chain reactions that lead to cell death. "A question was whether limonoids turn on apoptosis which then turn on the caspases and if so, whether that means there is caspases resting in our cells (that could be activated to help fight cancer in us)," he said.

This part of the research revealed that with only 5 micromoles of a limonoid known as LG, the cancer cells were dying in as little as 12 hours.

"The last phase in killing cancer is to make sure the DNA is destroyed because that is the death knell for the cell," Harris said. "It’s intriguing that this amount appeared to have no effect on normal cells and only certain types of cancer cells are vulnerable. Fortunately, breast cancer cells are on the list of vulnerable cells. This makes it all the more imperative to learn how the process works.

"We don’t have the answer to that yet," he said, "but we have observed that those limonoids with the greatest potency have a closed ring in their chemical structure and that is different from other compounds."

Limonoids with a sugar unit attached, the so-called limonoid glucosides, are water soluble and tasteless; those without the sugar, the aglycons, are responsible for bitterness of some citrus. It was the limonoid glucosides, in this study that had "a dramatic effect" on cancer cell death. "Now that we have seen the cancer cells die and in such a short time," Harris said, "we need to find out why they are so vulnerable and exploit it. It could be that ultimately we are able to give patients an oral cocktail of limonoids in such concentration as to stop their cancer."

Patil said the researchers also will be studying limonoids to find the limits for adding to food. One of the limonoids, glucoside, is tasteless, he noted, so it might become a food additive for its health benefits, but food engineers would need to know how much to add for human consumption.

His lab also is examining whether the compounds vary among citrus species and at different times of the year.

Kathleen Phillips | EurekAlert!
Further information:
http://www.tamu.edu

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

A new dead zone in the Indian Ocean could impact future marine nutrient balance

06.12.2016 | Earth Sciences

Significantly more productivity in USP lasers

06.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>